Cargando…

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

BACKGROUND: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Tejaswini P., Choi, Dong S., Anselme, Ann C., Qian, Wei, Chen, Wen, Lantto, Johan, Horak, Ivan D., Kragh, Michael, Chang, Jenny C., Rosato, Roberto R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227035/ https://www.ncbi.nlm.nih.gov/pubmed/32414394 http://dx.doi.org/10.1186/s13058-020-01280-z

Ejemplares similares

In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography
por: Nielsen, Carsten H., et al.
Publicado: (2015)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

The Potential of panHER Inhibition in Cancer
por: Wang, Xiaochun, et al.
Publicado: (2015)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies
por: Suárez, Narjara González, et al.
Publicado: (2017)

Erratum to: Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
por: Overholser, Jay, et al.
Publicado: (2015)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
por: Choi, Yunsik, et al.
Publicado: (2018)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics
por: Guilhamon, Paul, et al.
Publicado: (2014)

Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023)

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
por: Li, Ziteng, et al.
Publicado: (2020)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC
por: Sharma, Malvika, et al.
Publicado: (2021)

Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines
por: Woo, Xing Yi, et al.
Publicado: (2019)

Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
por: du Manoir, Stanislas, et al.
Publicado: (2013)

Pyridoxal phosphate synthases PdxS/PdxT are required for Actinobacillus pleuropneumoniae viability, stress tolerance and virulence
por: Xie, Fang, et al.
Publicado: (2017)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs
por: Punzi, Simona, et al.
Publicado: (2019)

Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
por: Affatato, Roberta, et al.
Publicado: (2020)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
por: MacNeil, Ian A., et al.
Publicado: (2022)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer
por: Alanazi, Ibrahim O., et al.
Publicado: (2021)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti-Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells
por: Novitasari, Dhania, et al.
Publicado: (2021)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
por: Chen, Wei, et al.
Publicado: (2017)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m7uh96agi6i34mjpf5nrva8e9c